C81.38
Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphocyte depleted Hodgkin lymphoma is a rare and aggressive form of Hodgkin lymphoma, a type of cancer that begins in the lymphatic system. Specifically, this subtype affects multiple lymph nodes and is characterized by a significant reduction in lymphocytes, which are a key type of immune cells. The condition tends to progress more rapidly compared to other forms and may involve other tissues or organs in the body. Proper diagnosis and prompt treatment are essential for managing this disease effectively.
Causes & Symptoms
Clinical Causes: The exact causes of lymphocyte depleted Hodgkin lymphoma are not well understood. It is believed to result from genetic mutations within lymphatic cells. Certain environmental factors or exposures to radiation and chemicals may increase risk, although no direct causation has been established. It may develop without clear risk factors, especially in individuals with compromised immune systems.
Key Symptoms: Swollen lymph nodes, often in multiple regions such as the neck, armpits, or groin Unexplained weight loss Fever that persists over time Night sweats Fatigue or feeling unusually tired Itching skin Persistent cough or chest discomfort if lymph nodes around the chest are involved Signs of infection or other organ involvement if the disease spreads
Diagnostic & Treatment
Diagnosis Path: Biopsy of affected lymph node tissue to examine the cellular structure and confirm the diagnosis Imaging studies such as CT scans or PET scans to assess the extent of disease spread Blood tests to evaluate overall health and immune function Bone marrow biopsy if bone marrow involvement is suspected Flow cytometry and immunohistochemistry to identify specific cell markers
Treatment Protocols: Chemotherapy regimens that combine multiple anti-cancer drugs to target rapidly dividing cells Radiation therapy to destroy cancerous tissues in specific areas Stem cell transplant may be considered in cases where the disease is resistant to initial treatments Targeted therapies or immunotherapy, which aim to enhance the patient's immune response against the cancer, are also evolving options Supportive care to manage side effects and maintain overall health during treatment
Clinical Advice & FAQs
Billing Guidance
Is C81.38 a billable ICD-10 code?
Yes, C81.38 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.38?
Clinical documentation must specify the nature of Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference